Laigo Bio develops SureTACs, bispecific antibodies that facilitate the targeted degradation of membrane proteins linked to tumors and neurological diseases by promoting their ubiquitination and subsequent lysosomal removal. This technology addresses the challenge of treating previously undruggable targets, enhancing therapeutic specificity and efficacy in oncology and beyond.
Funding
Funding not disclosed
Founders
Product
Problem
Many disease-causing proteins, particularly those on cell surfaces, are considered "undruggable" by traditional therapeutic approaches. Existing treatments often lack the specificity needed to target these proteins effectively, leading to off-target effects and limited efficacy.
Solution
Laigo Bio develops SureTACs (Surface Removal Targeting Chimeras), a novel class of bispecific antibodies designed to selectively degrade membrane proteins implicated in tumors and neurological disorders. SureTACs function by binding to both the target protein and a membrane-bound E3 ligase, promoting ubiquitination and subsequent lysosomal degradation of the target. This approach enables the removal of previously intractable targets, enhancing therapeutic precision and minimizing off-target interactions. Laigo Bio employs transcriptome and proteome analysis, along with a proprietary screening platform, to identify optimal target-ligase combinations tailored to specific disease indications.
Target Audience
Laigo Bio's primary target audience includes researchers and clinicians focused on developing targeted therapies for cancer, neurological diseases, and immunological disorders, as well as strategic partners seeking innovative approaches to address currently undruggable targets.
Features
- Bispecific antibody technology for targeted protein degradation
- Selective removal of disease-driving membrane targets
- Utilizes the ubiquitin-mediated lysosomal degradation pathway
- Targets previously "undruggable" proteins on the cell surface
- Employs membrane-bound E3 ligases for proximity-induced ubiquitination
- Screening platform to identify optimal target-ligase combinations
- Initial focus on oncology, with expansion into immunology and neuroinflammation